Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application

  • Signal Transduct Target Ther. 2020 Jun 5;5(1):76. doi: 10.1038/s41392-020-0177-z.
Afsaneh Sadremomtaz  1 ,  Ameena M Ali  1  2 ,  Foroozan Jouyandeh  3 ,  Saeed Balalaie  4 ,  Razieh Navari  4 ,  Sylvain Broussy  5 ,  Kamran Mansouri  6 ,  Matthew R Groves  7 ,  S Mohsen Asghari  8  9
Affiliations
  • 1. XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands.
  • 2. Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Doha, Qatar.
  • 3. Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
  • 4. Peptide Chemistry Research Center, K.N. Toosi University of Technology, K. N. Toosi University of Technology, Tehran, Iran.
  • 5. University of Paris, Faculty of Pharmacy of Paris, CiTCoM, 8038 CNRS, U 1268 INSERM, F-75006, Paris, France.
  • 6. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • 7. XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands. [email protected].
  • 8. Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran. [email protected].
  • 9. Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. [email protected].
PMID: 32499505 DOI: 10.1038/s41392-020-0177-z
Products